Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21941765 | 1.00 | OPRM1 (0.37) | OPRM1OPRD1OPRK1 | |
| SCHEMBL3191321 | 0.99 | OPRM1 (0.39) | OPRM1OPRD1OPRK1 | |
| SCHEMBL611541 | 0.99 | OPRM1 (0.39) | OPRM1OPRD1OPRK1 | |
| SCHEMBL10287095 | 0.99 | OPRM1 (0.39) | OPRM1OPRD1OPRK1 | |
| SCHEMBL612983 | 0.99 | OPRM1 (0.39) | OPRM1OPRD1OPRK1 | |
| SCHEMBL15463121 | 0.90 | NMT2 (0.42) | — | |
| SCHEMBL16031728 | 0.88 | PDE4A (0.35) | — | |
| SCHEMBL13559385 | 0.87 | MEN1 (0.43) | — | |
| SCHEMBL10235806 | 0.86 | BCHE (0.39) | OPRM1OPRD1OPRK1 | |
| SCHEMBL10235827 | 0.85 | BCHE (0.40) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | claimed |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | claimed |
| US-8076516-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2011-12-13 | — | — | US | claimed |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA, INC. (US) | 2009-11-12 | — | — | US | claimed |
| EP-2111223-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-10-28 | — | — | EP | claimed |
| WO-2009058216-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-05-07 | — | — | WO | claimed |
| US-11795136-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20210171435-A1 | Methods for the Treatment of Diabetic Retinopathy and other Ophthalmic Diseases | ACUCELA INC. | 2021-06-10 | — | — | US | disclosed |
| US-10730825-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC. (US) | 2020-08-04 | — | — | US | disclosed |
| EP-2844636-B1 | METHODS FOR THE TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY | ACUCELA INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-9957224-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9452153-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452153-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-8076516-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2111223-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009058216-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058216-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | OPRM1 2075/4885OPRD1 426/4885OPRK1 1063/4885 |
| US-10730825-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ALDH1A2, ALDH1A3, RBP4 | OPRM1 4053/4885OPRD1 3774/4885OPRK1 3029/4885 |
| US-11795136-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ALDH1A2, ALDH1A3, RBP4 | OPRM1 4053/4885OPRD1 3774/4885OPRK1 3029/4885 |
| US-20210171435-A1 | Methods for the Treatment of Diabetic Retinopathy and other Ophthalmic Diseases | ALDH1A2, ALDH1A3, RBP4 | OPRM1 4053/4885OPRD1 3774/4885OPRK1 3029/4885 |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | OPRM1 2075/4885OPRD1 426/4885OPRK1 1063/4885 |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | PDE6D, CLN6, AADAT | OPRM1 2075/4885OPRD1 426/4885OPRK1 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.